blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4514397

EP4514397 - COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN BINDING MOLECULES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  31.01.2025
Database last updated on 28.02.2026
FormerThe international publication has been made
Status updated on  03.11.2023
Most recent event   Tooltip04.07.2025Change: Validation statespublished on 06.08.2025  [2025/32]
04.07.2025Change - extension statespublished on 06.08.2025  [2025/32]
Applicant(s)For all designated states
Asher Biotherapeutics, Inc.
650 Gateway Blvd., Suite 100
South San Francisco, CA 94080 / US
[2025/10]
Inventor(s)01 / DJURETIC, Ivana
South San Francisco, California 94080 / US
02 / GREER, Renee L.
South San Francisco, California 94080 / US
03 / YEUNG, Yik Andy
South San Francisco, California 94080 / US
 [2025/10]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[2025/10]
Application number, filing date23797206.226.04.2023
[2025/10]
WO2023US19989
Priority number, dateUS202263335697P27.04.2022         Original published format: US 202263335697 P
[2025/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2023212056
Date:02.11.2023
Language:EN
[2023/44]
Type: A2 Application without search report 
No.:EP4514397
Date:05.03.2025
Language:EN
The application published by WIPO in one of the EPO official languages on 02.11.2023 takes the place of the publication of the European patent application.
[2025/10]
Search report(s)International search report - published on:US07.12.2023
ClassificationIPC:A61K47/68, C07K16/28, A61K38/20, A61K39/395, C12P21/08, A61P37/02, C07K14/54
[2025/10]
CPC:
C07K14/55 (EP,KR,US); A61K38/20 (EP,KR,US); A61K39/39541 (US);
A61K38/2013 (EP,KR,US); A61P31/00 (KR); A61P35/00 (EP,KR,US);
A61P37/02 (KR); C07K14/54 (EP,KR,US); C07K16/2815 (KR,US);
A61K2039/505 (US); A61K2300/00 (KR); C07K2319/00 (EP,KR,US) (-)
C-Set:
A61K38/2013, A61K2300/00 (EP);
A61K38/20, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2025/10]
TitleGerman:KOMBINATION VON CYTOKINFUSIONSPROTEINEN MIT CD8-ANTIGEN-BINDENDEN MOLEKÜLEN[2025/10]
English:COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN BINDING MOLECULES[2025/10]
French:COMBINAISON DE PROTÉINES DE FUSION DE CYTOKINES AVEC DES MOLÉCULES DE LIAISON À L'ANTIGÈNE CD8[2025/10]
Entry into regional phase12.11.2024National basic fee paid 
12.11.2024Search fee paid 
12.11.2024Designation fee(s) paid 
12.11.2024Examination fee paid 
Examination procedure12.11.2024Examination requested  [2025/10]
27.05.2025Amendment by applicant (claims and/or description)
Fees paidRenewal fee
28.04.2025Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X] US2020330514  (ANDRESEN THOMAS L et al.) [X] 1, 56-60, 68, 69 * entire document. *
 [Y] US2022112288  (GANESAN RAJKUMAR et al.) [Y] 11, 62-64 * entire document *
 [Y] WO2022006380  (INHIBRX INC et al.) [Y] 65, 67 * entire document *
 [Y] US2022033455  (WONG HING C et al.) [Y] 66 * entire document *
 [XY]   ANONYMOUS: "Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting", ASHERBIO, 4 August 2022 (2022-08-04), XP093118477, Retrieved from the Internet [retrieved on 20240111] [X] 1-10, 46, 61 * . entire document *[Y] 11, 62-67
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.